Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $22.80 in the prior trading day, Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) closed at $21.69, down -4.87%. In other words, the price has decreased by -$4.87 from its previous closing price. On the day, 1.22 million shares were traded. CPRX stock price reached its highest trading level at $22.7317 during the session, while it also had its lowest trading level at $21.53.
Ratios:
Our goal is to gain a better understanding of CPRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.76. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.11. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 14, 2024, initiated with a Buy rating and assigned the stock a target price of $27.
On March 07, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $23.
On December 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $30.Oppenheimer initiated its Outperform rating on December 21, 2023, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 14 ’24 when MCENANY PATRICK J bought 44,655 shares for $21.75 per share.
MCENANY PATRICK J sold 262,000 shares of CPRX for $6,094,062 on Nov 12 ’24. The Chairman of Board of Directors now owns 4,478,169 shares after completing the transaction at $23.26 per share. On Nov 11 ’24, another insider, MCENANY PATRICK J, who serves as the Chairman of Board of Directors of the company, sold 230,000 shares for $23.55 each. As a result, the insider received 5,416,040 and left with 4,478,169 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2719427072 and an Enterprise Value of 2147991808. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.51, and their Forward P/E ratio for the next fiscal year is 14.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.62 while its Price-to-Book (P/B) ratio in mrq is 3.91. Its current Enterprise Value per Revenue stands at 4.665 whereas that against EBITDA is 10.159.
Stock Price History:
Over the past 52 weeks, CPRX has reached a high of $24.27, while it has fallen to a 52-week low of $12.90. The 50-Day Moving Average of the stock is 3.44%, while the 200-Day Moving Average is calculated to be 24.76%.
Shares Statistics:
The stock has traded on average 958.06K shares per day over the past 3-months and 1293720 shares per day over the last 10 days, according to various share statistics. A total of 107.12M shares are outstanding, with a floating share count of 102.94M. Insiders hold about 13.70% of the company’s shares, while institutions hold 76.30% stake in the company. Shares short for CPRX as of 1730332800 were 6014699 with a Short Ratio of 6.28, compared to 1727654400 on 5751460. Therefore, it implies a Short% of Shares Outstanding of 6014699 and a Short% of Float of 6.25.
Earnings Estimates
The stock of Catalyst Pharmaceuticals Inc (CPRX) is currently drawing attention from 5.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.44, with high estimates of $0.52 and low estimates of $0.27.
Analysts are recommending an EPS of between $2.1 and $1.98 for the fiscal current year, implying an average EPS of $2.04. EPS for the following year is $2.09, with 5.0 analysts recommending between $2.47 and $1.16.
Revenue Estimates
7 analysts predict $133.71M in revenue for the current quarter. It ranges from a high estimate of $137.41M to a low estimate of $130.39M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $110.57MFor the next quarter, 7 analysts are estimating revenue of $128.58M. There is a high estimate of $134.34M for the next quarter, whereas the lowest estimate is $120M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $487.33M, while the lowest revenue estimate was $480.31M, resulting in an average revenue estimate of $483.62M. In the same quarter a year ago, actual revenue was $398.2MBased on 7 analysts’ estimates, the company’s revenue will be $567.38M in the next fiscal year. The high estimate is $603.2M and the low estimate is $555.38M.
